Go To Global Site
Welcome to UCB in the United States

Apr

23

"The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis

Apr

23

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021 

Apr

23

UCB Showcases Approach to Creating Patient Value in Immuno-Dermatology

At UCB, we have come to develop a deep understanding of the patient experience and the unmet needs of people living with immuno-dermatological conditions. As we join for the American Academy of Dermatology VMX 2021 Conference, read from Rhonda Peebles, our Head of U.S. Dermatology, on UCB’s approach to creating value for patients.

Feb

05

The Lancet Publishes Two Phase 3 Studies Detailing Bimekizumab Data in Moderate to Severe Plaque Psoriasis

Oct

31

Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira® in Moderate-to-Severe Psoriasis Patients

Sep

10

Improving Diversity in Dermatology

UCB is participating in the Skin of Color Update (“SOCU”) Dermatology Conference, a forum for medical specialists to discuss trending evidence-based research and best practices for skin of color in dermatology. This year’s SOCU comes at an important time for the healthcare community and serves as an opportunity to have conversations and problem solve around inequities in dermatological care. Read more from Rhonda Peebles, Head of U.S. Dermatology, as she shares her thoughts on racial inequities in dermatology and the steps UCB is taking to move the equity needle forward. 

Aug

11

The Impact of Psoriasis: Infographic

At UCB, we are committed to supporting the psoriasis community and working to improve the future for those living with the disease. In honor of Psoriasis Awareness Month, we’re shining a spotlight on the over 7 million people in the U.S. impacted by psoriasis every day.

Jun

11

Empowering Patients Impacted by Immuno-Dermatological Conditions

At UCB, everything we do starts with one simple question: “How will this make a difference in the lives of people living with severe diseases?” This question is our motivation, inspiration and what challenges us to stay focused on what will ultimately benefit the patients we serve. Read more from Camille Lee, Head of U.S. Immunology, about how UCB is working to empower patients impacted by immuno-dermatological conditions.